Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RM-131 · 5 trials · 8 indications
Change from baseline colonic geometric center at 24 hours
Change from baseline in body weight.
Change from baseline in gastric half-emptying time (t½)
Change from baseline HAPC
Change from baseline in gastric half-emptying time by scintigraphy (solids and liquids)
| Arm | Type | Description |
|---|---|---|
| RM-131 | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RM-131 | DRUG | Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days. |
| Placebo | DRUG | Placebo delivered subcutaneously once daily for 14 days. |
Inclusion criteria * Able to provide written informed consent prior to any study procedures, and willing and able to comply with study procedures. * Diagnosis of chronic IDIOPATHIC constipation, including experiencing constipation for 12 or more weeks in the preceding 12 months (defined by Rome III...
RM-131 is an investigational small molecule being studied for multiple conditions, including diabetic gastroparesis in patients with type 1 or type 2 diabetes, anorexia nervosa, and chronic constipation. It has been evaluated in Phase 2 clinical trials for these indications, though it remains investigational and is not approved.
RM-131 is being developed by Rhythm Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker RYTM. The company has sponsored clinical trials of RM-131 in the United States across several gastrointestinal and psychiatric indications.
RM-131 has completed Phase 2 clinical trials for diabetic gastroparesis, anorexia nervosa, and chronic constipation, as well as a Phase 1 study for chronic constipation. It is an investigational drug still in clinical development and has not been approved by regulatory authorities.
RM-131 has been studied in several completed trials, including NCT01571297, a Phase 2 study in 204 patients with diabetic gastroparesis; NCT01642550, a Phase 2 pilot in 20 females with anorexia nervosa; NCT01781104, a Phase 2 study in 48 patients with chronic constipation; and NCT02137642, a Phase 1 study in 18 patients with chronic constipation.
RM-131 is the investigational name used by Rhythm Pharmaceuticals for this small molecule compound. No alternative names have been reported in the clinical trial records, so it is not known to be marketed under any other designation.